Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 6597387, 8 pages
https://doi.org/10.1155/2018/6597387
Research Article

Copeptin as a Prognostic Marker in Acute Chest Pain and Suspected Acute Coronary Syndrome

12nd Department of Cardiology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, M. Skłodowskiej-Curie 10, 41-800 Zabrze, Poland
2Department of Cardiology, Tuen Mun Hospital, 23 Tsing Chung Koon Rd, Tuen Mun, Hong Kong
3Department of Accident and Emergency, Tuen Mun Hospital, 23 Tsing Chung Koon Rd, Tuen Mun, Hong Kong
4Department of Cardiology, Lausanne University Hospital, rue du Bugnon 46, 1011 Lausanne, Switzerland

Correspondence should be addressed to Beata Morawiec; lp.pw@ceiwaromaeb

Received 7 June 2017; Revised 25 August 2017; Accepted 18 October 2017; Published 24 January 2018

Academic Editor: Salvatore Di Somma

Copyright © 2018 Beata Morawiec et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Roffi, C. Patrono, J. P. Collet et al., “2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 37, no. 3, pp. 267–315, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Thygesen, J. S. Alpert, H. D. White, and Joint ESCAAHAWHFTFftRoMI, “Universal definition of myocardial infarction,” European Heart Journal, vol. 28, no. 20, pp. 2525–2538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. M. L. O'Donoghue, D. A. Morrow, C. P. Cannon et al., “Multimarker risk stratification in patients with acute myocardial infarction,” Journal of the American Heart Association, vol. 5, no. 5, article e002586, 2016. View at Publisher · View at Google Scholar
  4. B. Morawiec and D. Kawecki, “Copeptin: a new marker in cardiology,” Journal of Cardiovascular Medicine, vol. 14, no. 1, pp. 19–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. C. T. Lui, H. Lam, K. H. Cheung et al., “Role of copeptin in dual-cardiac marker strategy for patients with chest pain presented to ED,” The American Journal of Emergency Medicine, vol. 33, no. 12, pp. 1732–1736, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Q. Khan, O. S. Dhillon, R. J. O'Brien et al., “C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study,” Circulation, vol. 115, no. 16, pp. 2103–2110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Reichlin, W. Hochholzer, C. Stelzig et al., “Incremental value of copeptin for rapid rule out of acute myocardial infarction,” Journal of the American College of Cardiology, vol. 54, no. 1, pp. 60–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Voors, S. von Haehling, S. D. Anker et al., “C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study,” European Heart Journal, vol. 30, no. 10, pp. 1187–1194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Morawiec, D. Kawecki, L. Ho, L. Chun Tat, O. Muller, and E. Nowalany-Kozielska, “COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) Study: design and objectives,” Advances in Interventional Cardiology, vol. 12, no. 46, pp. 1–4, 2016. View at Google Scholar
  10. M. Mockel, J. Searle, C. Hamm et al., “Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study,” European Heart Journal, vol. 36, no. 6, pp. 369–376, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Zellweger, K. Wildi, R. Twerenbold et al., “Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction,” International Journal of Cardiology, vol. 190, pp. 190–197, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Balmelli, C. Meune, R. Twerenbold et al., “Comparison of the performances of cardiac troponins, including sensitive assays, and copeptin in the diagnostic of acute myocardial infarction and long-term prognosis between women and men,” American Heart Journal, vol. 166, no. 1, pp. 30–37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 37, no. 27, pp. 2129–2200, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. F. D'Ascenzo, G. Biondi-Zoccai, C. Moretti et al., “TIMI, GRACE and alternative risk scores in acute coronary syndromes: a meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients,” Contemporary Clinical Trials, vol. 33, no. 3, pp. 507–514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Manfrini and R. Bugiardini, “Barriers to clinical risk scores adoption,” European Heart Journal, vol. 28, no. 9, pp. 1045-1046, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. R. G. O'Malley, M. P. Bonaca, B. M. Scirica et al., “Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome,” Journal of the American College of Cardiology, vol. 63, no. 16, pp. 1644–1653, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. V. C. Vasile, L. Babuin, E. Giannitsis, H. A. Katus, and A. S. Jaffe, “Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction,” Clinical Chemistry, vol. 54, no. 3, pp. 617–619, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Reynolds, M. Cecconi, P. Collinson, A. Rhodes, R. M. Grounds, and M. A. Hamilton, “Raised serum cardiac troponin I concentrations predict hospital mortality in intensive care unit patients,” British Journal of Anaesthesia, vol. 109, no. 2, pp. 219–224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Ananth, J. R. Beig, N. A. Tramboo et al., “Does plasma copeptin level at admission predict final infarct size in ST-elevation myocardial infarction,” International Journal of Cardiology, vol. 219, pp. 326–330, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Maisel, C. Mueller, K. Adams et al., “State of the art: using natriuretic peptide levels in clinical practice,” European Journal of Heart Failure, vol. 10, no. 9, pp. 824–839, 2008. View at Publisher · View at Google Scholar · View at Scopus